Fortress Biotech, Inc. (FBIO)
2.93
+0.06
(+2.09%)
USD |
NASDAQ |
Aug 24, 16:00
2.93
0.00 (0.00%)
After-Hours: 20:00
Fortress Biotech Gross Profit Margin (Quarterly) : 61.50% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 61.50% |
| March 31, 2026 | 53.63% |
| December 31, 2025 | 58.97% |
| September 30, 2025 | 60.80% |
| June 30, 2025 | 62.86% |
| March 31, 2025 | 54.48% |
| December 31, 2024 | 61.61% |
| September 30, 2024 | 63.19% |
| June 30, 2024 | 53.40% |
| March 31, 2024 | 44.80% |
| December 31, 2023 | 67.95% |
| September 30, 2023 | 80.35% |
| June 30, 2023 | 50.72% |
| March 31, 2023 | 41.32% |
| December 31, 2022 | 47.93% |
| September 30, 2022 | 51.47% |
| June 30, 2022 | 55.58% |
| March 31, 2022 | 62.62% |
| December 31, 2021 | 43.72% |
| September 30, 2021 | 43.93% |
| June 30, 2021 | 54.64% |
| March 31, 2021 | 61.07% |
| December 31, 2020 | 64.47% |
| Date | Value |
|---|---|
| September 30, 2020 | 49.93% |
| June 30, 2020 | 60.62% |
| March 31, 2020 | 66.43% |
| December 31, 2019 | 63.45% |
| September 30, 2019 | 67.48% |
| June 30, 2019 | 69.26% |
| March 31, 2019 | 63.49% |
| September 30, 2018 | 65.30% |
| June 30, 2018 | 71.02% |
| March 31, 2018 | 71.74% |
| December 31, 2017 | 94.74% |
| September 30, 2017 | 97.84% |
| June 30, 2017 | 97.28% |
| March 31, 2017 | 97.82% |
| December 31, 2016 | 94.21% |
| September 30, 2016 | 80.00% |
| June 30, 2016 | 82.33% |
| March 31, 2016 | 0.00% |
| December 31, 2015 | 0.00% |
| September 30, 2015 | 0.00% |
| June 30, 2015 | |
| March 31, 2015 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | -- |
| Ironwood Pharmaceuticals, Inc. | 99.60% |
| Kura Oncology, Inc. | 97.07% |
| Spero Therapeutics, Inc. | -- |
| Cue Biopharma, Inc. | 99.54% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 123.2% |
| Return on Assets | 58.81% |
| Return on Invested Capital | 79.78% |
| Profit Margin (Quarterly) | 3.22% |
| Operating Margin (Quarterly) | -53.46% |
| Return on Net Operating Assets | 182.0% |